Trial Evaluating Devil's Claw for the Treatment of Hip and Knee Osteoarthritis

Osteoarthritis, Knee Clinical Trial

Official title:

A Randomized, Double-blind, Placebo-controlled, Dose-ranging Two- Centre Study to Evaluate the Efficacy and Safety of Devil's Claw in the Treatment of Knee and Hip Osteoarthritis

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00295490
• Other study ID #: devilclaw1
• Status: Terminated
• Phase: Phase 2
• First received: February 21, 2006
• Last updated: September 9, 2011
• Start date: December 2004
• Est. completion date: June 2008

Study information

• Verified date: September 2011
• Source: University of Southampton
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Department of Health
• Study type: Interventional

Clinical Trial Summary

Osteoarthritis of both the knee and hip joints are common conditions; knee osteoarthritis affects 6% of adults over 30 years of age and osteoarthritis of the hip affects between 3% and 6% of the Caucasian population. Both forms of osteoarthritis are associated with disability. Conventional treatment (analgesics and the use non-steroidal anti-inflammatory, NSAIDS) is prophylactic, aimed at decreasing pain and improving function. However long term use of NSAIDS is associated with a high incidence of adverse events (gastrointestinal tract symptoms). A safer alternative treatment would therefore be beneficial.

Both anecdotal evidence and recent studies have implicated the potential of the herbal remedy Devil's Claw (Harpagophytum procumbens) for the treatment of painful, chronic arthritic type conditions (Ernst and Chrubasik, 2000). Devil's Claw is an extract obtained from the root of the Harpagophytum procumbens plant, a member of the sesame family found in the Kalahari region in South Africa. It has been shown that this herbal remedy has anti-inflammatory and analgesic effects (Baghdikian et al, 1997). Currently Devil's Claw is marketed for use as a supportive treatment of degenerative arthrosis, is not a Medicines Control Agency licensed product and is freely available to the general public in health food stores and pharmacies.

The objectives of this study are to assess the efficacy, optimum dosage and safety of the herbal remedy Devil's Claw (Harpagophytum) in the treatment of osteoarthritis of the knee and/or hip. The primary objective of this study is to investigate the following three principal questions:

1. To compare the efficacy of Devil's Claw with placebo in the treatment of osteoarthritis of the knee and/or hip

2. To determine the optimum dose of Devil's Claw and

3. To evaluate the safety and tolerability of three doses of Devil's Claw in the treatment of osteoarthritis of the knee/hip and to compare them to placebo There are also a number of secondary research objectives that will also be addressed (see later).

These objectives are based on the following hypotheses :

Hypotheses

• Devil's Claw has anti-inflammatory properties (as assessed by the reduction in pain, stiffness and disability aspects on the WOMAC) in chronic osteoarthritis of the knee and/or hip after 16 weeks of treatment, as compared to placebo.

• A dose response effect exists in the treatment of osteoarthritis of the knee/hip by Devil's Claw.

Description:

STUDY DESIGN: Randomized, placebo-controlled, dose-ranging two-centre study PREPARATIONS FOR INVESTIGATION: Devil's Claw (Allya®)/placebo as tablets

STATISTICAL METHODS:

Analysis on an intention to treat basis.

The following tests will be performed and all statistical significance will be set at p < 0.05:

Primary efficacy analysis: The primary outcome will be the reduction in WOMAC total score from baseline to week 16. The week 16 means for the four treatment groups will be compared using an analysis of covariance taking account of baseline assessments and any demographic differences, age, gender, etc, which are found to be significant. Multiple comparison tests will be used to examine specific differences of initially specified interest, such as the two highest doses of Devil's Claw versus placebo.

Secondary Efficacy Analysis: Similar analyses of covariance will be used to examine treatment group differences at week 16 compared with baseline for WOMAC subscales (pain, stiffness and physical function), and Quality of Life assessments (SF-36). Changes in the subject's well-being and overall global assessment will be compared using appropriate non-parametric tests, e.g. Mann-Whitney test or MacNemar's test. Changes in attitudes and health beliefs to CAM will be assessed using Chi-Squared tests.

Safety Evaluation: Group differences between adverse event reporting will be assessed by descriptive methods.

NUMBER OF PATIENTS:

264 (50 patients in each group, with an expected total of 64 drop-outs) NUMBER OF SITES: 2

TIME SCHEDULE:

Study Start: April 2004 Study End: March 2007 Observation period/patient: 20 weeks

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 67
• Est. completion date: June 2008
• Est. primary completion date: November 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• Patients with either a pragmatic diagnosis of osteoarthritis of the knee, with no other known rheumatological condition and who report the following clinical features (based on the ACR classification for knee OA1):

• knee pain on most days of the previous month

• morning stiffness of less than 30 minutes duration

• "stiffness" in resting the joint and and are aged over 40 years

• osteoarthritis of the hip, with no other known rheumatological condition and who report the following clinical features (based on the ACR classification for hip OA2):

• hip pain on most days of the previous month and at least two of the following 3 features:

• ESR < 20mm/hour

• Radiographic femoral or acetabular osteophytes

• Radiographic joint space narrowing (superior, axial and/or medial)

• And are aged over 45 years of age

• The diagnosis of osteoarthritis will be confirmed by X-ray. Only patients who have grade 2 to 4 of the Kellgren and Lawrence scale will be recruited. (The Kellgren and Lawrence scale ranges from grade 0 to grade 4 where grades 0 and 1 represent doubtful osteoarthritic changes and therefore a doubtful diagnosis.)

• Patients who have been on stable medication (conventional or complementary, including nutritional medicine) for the past three months, but are still getting symptoms (incomplete responders)

• Only those patients who record baseline pain scores on the WOMAC scale of at least 20 mm on the VAS for a minimum of 6 out of 7 days monitored during the period from Clinic Visit 1 (screening) and Clinic Visit 2 (baseline)

• Ability to comply with the requirements of the study and to give informed consent

• For women of child-bearing potential: negative pregnancy test

Exclusion Criteria:

• Participation in an investigational trial within 30 days prior to enrollment

• Previous treatment with Devil' s Claw within 90 days prior to enrollment

• Patients awaiting a replacement knee or hip joint

• Patients with other conditions that cause pain

• Patients with congenital dislocation of the hip

• Patients who have had operations on their hip due to previous trauma

• Patients with severe co-morbidities - including severe cardiac or pulmonary disease and cancer

• Dementia, psychoses, or other significant impairment of mental status that would prohibit sufficient comprehension, provision of informed consent and to allow undertaking of the necessary self-care or toxicity reporting

• Patients taking corticosteroid medication

• Known allergies against any of the ingredients of the treatments

• Patients who would be unable to complete the self assessment forms, or to attend for X-ray and clinical examination

• Patients with other known rheumatic disease such as rheumatoid arthritis

• Patients with the diagnosis gout

• Patients who report a red or hot swollen joint (which is unlikely to be due to OA), and would require further rheumatological assessment

• Patients with conditions known to be contraindicated to the study medication i.e. patients with gastric or duodenal ulcers; gallstones; patients taking drugs for arrhythmias; patients with heart failure

• Patients who are pregnant, trying to become pregnant or breastfeeding

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Osteoarthritis
• Osteoarthritis, Hip
• Osteoarthritis, Knee

Intervention

Drug:
• Devil Claw
Dose ranging study so will elucidate dose Frequency is four times daily
• Placebo
Placebo has same dosing freq as for active intervention and for same time period

Locations

Country	Name	City	State
United Kingdom	Wellcome Trust Clinical Research Facility, Southampton General Hospital	Southampton	Hants

Sponsors (2)

Lead Sponsor	Collaborator
University of Southampton	Pascoe Pharmazeutische Praeparate GmbH

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Western Ontario and Mc Master University OA Index (WOMAC)	WOMAC is a disease specific outcome measure for osteoarthritis. It has three subscales assessing pain (5 questions), stiffness (2 questions) and function (15 questions). together the subscales give an overall total score ranging from 0 (worst) to 100 (best; an increase in total score indicates an improvement in health. THe outcome was measured at baseline, week 8 and week 16. In this study the primary outcome was the reduction in WOMAC total score from baseline to the end of treatment at week 16.	Baseline, week 8 and week 16	No
Secondary	Pain Subscale on Western Ontario and Mc Master University OA Index	Subscale assessed by 100mm VAS based on five questions addressing pain in osteoarthritis using the terminators no pain (0mm) to extreme pain (100mm). a higher score therefore indicates more severe pain. This outcome was recorded at baseline, week 8 and week 16 (end of treatment). The outcome for this study was reported as the change in WOMAC pain score from baseline to end of treatment at week 16.	Baseline, week 8 and week 16	No
Secondary	Disability Subscale on The Western Ontario and Mc Master University OA Index	Subscale assessed by 100mm VAS based on twelve questions addressing disability in osteoarthritis with a higher score indicating worse symptoms. The VAS used terminators of no disability (0mm) to extreme disability (100mm). The measure was recorded at baseline, week 8 and week 16. We reported the outcome as the change from baseline to end of treatment at week 16.	baseline, 8 and 16 weeks	No
Secondary	Stiffness Subscale on the The Western Ontario and Mc Master University OA Index	Subscale assessed by 100mm VAS based on two questions addressing stiffness in osteoarthritis;a higher score indicating worse symptoms. The VAS used terminators of no stiffness (0mm) to extreme stiffness (100mm). The measure was recorded at baseline, week 8 and week 16. We reported the outcome as the change from baseline to end of treatment at week 16.	Baseline, week 8 and week 16	No
Secondary	Short Form-36 (SF-36)	Quality of Life assessment containing 8 scales clustered into 2 summary scales: physical health and mental health. Each question is scored out from 0 (indicating worst health) to 100 (indicating best health). Mean scores for the 8 scales (total scores/no questions completed) are calculated to give a total score for each of the two summary scales between 0 (worst health) and 100 (best health). SF36 was recorded at baseline, week 8 and at the end of treatment at week 16. we reported the change from baseline to end of treatment as the outcome.	Baseline, week 8 and week 16	No
Secondary	Patient Global Assessment	To assess changes in the subject's well-being based on 7 point likert scale ranging from very poor (0 point) to very good (7 point). Outcome was recorded at baseline, week 8 and end of treatment at week 16. We reported outcome as the change in patient global assessment from baseline to end of treatment at week 16.	Baseline, week 8 and week 16	No
Secondary	Complementary and Alternative Medicine Beliefs Inventory	Questionnaire to assess changes in attitudes and health beliefs to CAM.the questionnaire as 17 questions, each scored on a 7 point likert scale from strongly disagree to strongly agree; a higher score indicates stronger belief in the measure. Minimum score 17, maximum score 119	four monthly	No
Secondary	Adverse Event Reporting	To identify Group differences between the number of adverse event recorded by patient for both serious and non serious adverse events, as well as events considered being attributable to the study medication.	Baseline and weeks 2,4,6,8,12 and 16	Yes